Related Experiment Video
Updated: Jan 24, 2026
02:22
Full-Endoscopic Surgery for Hypothalamic Hamartoma Resection
Published on: April 12, 2024
917
Leksell Radiosurgery for Ependymomas and Oligodendrogliomas
Hideyuki Kano1, L Dade Lunsford2
1Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, kanoh@upmc.edu.
Progress in Neurological Surgery
|May 17, 2019
Summary
Stereotactic radiosurgery (SRS) is a key treatment for rare glial tumors like ependymomas and oligodendrogliomas. It can be used as a primary, boost, or salvage therapy, with molecular markers aiding prognosis and treatment decisions.
Area of Science:
- Neuro-oncology
- Radiation Oncology
Background:
- Stereotactic radiosurgery (SRS) is increasingly used for less common glial tumors.
- Ependymomas and oligodendrogliomas are rare glial tumors requiring specialized management.
Purpose of the Study:
- To examine the role of SRS in managing recurrent or progressive ependymomas and oligodendrogliomas.
- To explore SRS as a primary, adjuvant, or salvage strategy for these tumors.
Main Methods:
- Review of current clinical practices and literature on SRS for ependymomas and oligodendrogliomas.
- Consideration of the impact of molecular markers on treatment selection and outcomes.
Main Results:
- SRS is a viable option for recurrent/progressive ependymomas post-radiation.
- SRS can serve as a primary or adjuvant therapy for oligodendrogliomas, especially in smaller tumors or post-progression.
Conclusions:
- SRS plays a significant role in the management of specific pediatric glial tumors.
- Molecular markers are becoming crucial for personalizing SRS treatment and predicting outcomes for these rare tumors.
